Back
Science

Review Synthesizes Research on Pseudogene-Derived lncRNAs in Cancer Stem Cell Regulation

Generated on: Last updated: 1 sources
View source

Pseudogene-Derived RNAs: New Regulators of Cancer Stem Cells

A recent review article in the journal Genes & Diseases consolidates current scientific research on the role of pseudogene-derived long non-coding RNAs (lncRNAs) in regulating cancer stem cells (CSCs). The review, authored by researchers from Shahrekord, Tehran, and Babol Universities of Medical Sciences, details the mechanisms by which these molecules influence CSC biology and their potential implications for cancer diagnosis and treatment.

Scientific Background

Cancer Stem Cells (CSCs) are a subpopulation of cells within tumors that are associated with cancer initiation, progression, metastasis, relapse, and resistance to therapy.

Pseudogene-Derived lncRNAs are RNA transcripts originating from pseudogenes, which were historically considered non-functional genomic artifacts. Current research recognizes them as active regulators of gene expression with structural similarity to conventional lncRNAs.

Reported Regulatory Mechanisms

The review states that pseudogene-derived lncRNAs influence CSC dynamics through several molecular mechanisms:

  • Acting as competitive endogenous RNAs (ceRNAs), which sequester microRNAs (miRNAs) and prevent them from binding to their target messenger RNAs, thereby altering gene expression.
  • Engaging in antisense regulation.
  • Interacting directly with proteins.

Through these actions, the review notes these molecules can affect key signaling pathways that control CSC properties, including the Wnt/β-catenin, PI3K/AKT, TGF-β, ERK, and JAK-STAT pathways.

Specific Examples in Cancer Types

The article details specific pseudogene-derived lncRNAs and their reported associations with either promoting or suppressing cancer stemness in various malignancies.

Reported Associations with Promoting Cancer Stemness
  • CYP4Z2P: Associated with enhanced CSC traits and chemoresistance in breast cancer.
  • RPSAP52: Associated with enhanced CSC traits in glioblastoma.
  • RSU1P2: Part of an axis (RSU1P2/let-7a/Tex10) reported to activate the Wnt/β-catenin pathway in liver cancer.
  • PDIA3P1: Reported to interact with the OCT4 protein in esophageal squamous cell carcinoma.
  • ZNF204P: Associated with promoted stemness and poorer patient outcomes in hepatocellular carcinoma.
Reported Associations with Suppressing Cancer Stemness
  • TPTEP1: Associated with suppressed cancer stemness in glioma.
  • GUSBP11: Associated with suppressed cancer stemness in triple-negative breast cancer.
  • AZGP1P2: Associated with suppressed cancer stemness in prostate cancer.
  • LPAL2: Associated with inhibited stemness in hepatocellular carcinoma.

Research Applications and Implications

The review states that expression levels of these lncRNAs can correlate with tumor grade and patient outcomes, suggesting their potential as diagnostic and prognostic biomarkers.

The article outlines a common research pipeline for studying these molecules, which includes:

  1. Discovery via high-throughput RNA sequencing and bioinformatics analysis.
  2. Validation using techniques such as RT-qPCR and fluorescence in situ hybridization (FISH).
  3. Functional investigation through CRISPR/Cas9 or siRNA-mediated modulation.
  4. Mechanistic mapping using biochemical assays like RNA immunoprecipitation (RIP) and dual-luciferase reporter assays.

The review provides a synthesis of current knowledge on the biogenesis, associated signaling pathways, and dual regulatory roles of pseudogene-derived lncRNAs in modulating cancer stemness.